GlassScriptPhysician profile
Adam B Elfant
NPI 1508930298
$385,444.19
in general payments reported to CMS, 2019-2025
33 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $45K · 2021: $68K · 2022: $44K · 2023: $37K · 2024: $62K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Food and Beverage: $7,121 · Travel and Lodging: $5,972 · Consulting Fee: $4,183 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,900.00 |
| Food and Beverage | $7,121.38 |
| Travel and Lodging | $5,971.93 |
| Consulting Fee | $4,182.50 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347,833.86 | 2019-2025 | |
| Boston Scientific Corporation | $19,418.76 | 2021-2025 | Exalt Model D, Acquire, Dreamtome Rx 49 |
| Ambu INC. | $11,264.58 | 2020-2024 | |
| Ambu A/S | $4,182.50 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $577.34 | 2021-2024 | Gattex, Entyvio, Eohilia |
| Janssen Biotech, INC. | $335.51 | 2021-2025 | Stelara, Simponi, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.42 | 2020-2025 | Xifaxan, Trulance |
| Celgene Corporation | $243.96 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $192.18 | 2022-2025 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $144.78 | 2024-2025 | Fujifilm |
| Celltrion USA INC. | $122.98 | 2025 | Zymfentra |
| Lilly USA, LLC | $74.16 | 2024-2025 | Omvoh |
| Pfizer INC. | $73.62 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $71.77 | 2025 | Zenpep |
| Erbe USA INC | $70.00 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $62.74 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $57.25 | 2021-2023 | |
| Amgen INC. | $53.13 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Olympus America INC. | $44.20 | 2022-2025 | Single Use Repositionable Clip, Endoclot Phs |
| Merck Sharp & Dohme LLC | $42.37 | 2022-2023 | Dificid |
| Romark Laboratories, Lc | $34.93 | 2020 | |
| Gilead Sciences, INC. | $31.85 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $30.78 | 2023 | Linzess |
| Ardelyx, INC. | $21.45 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $20.25 | 2024 | |
| Novo Nordisk INC | $19.86 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $19.12 | 2024 | Bylvay |
| Madrigal Pharmaceuticals | $16.08 | 2025 | Rezdiffra |
| Steris Corporation | $15.63 | 2021 | |
| Cook Medical LLC | $14.93 | 2021 | |
| Shionogi INC | $14.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.08 | 2025 | Voquezna |
| Redhill Biopharma INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Elfant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.